SEHK:2005
SEHK:2005Pharmaceuticals

How Investors Are Reacting To SSY Group (SEHK:2005) Winning Approval For Its Vitamin B6 Injection

SSY Group Limited recently announced that its Vitamin B6 Injection received approval from the National Medical Products Administration of China for the Consistency Evaluation of the Quality and Efficacy of Generic Drugs. This regulatory milestone broadens SSY Group’s product range and could improve treatment access for individuals affected by vitamin B6 deficiency in China. We'll explore how this regulatory approval in China could influence SSY Group’s investment narrative, particularly...
SEHK:2333
SEHK:2333Auto

How Investors May Respond To Great Wall Motor (SEHK:2333) Expanding Dual Inverter Partnership With BorgWarner

On October 30, 2025, BorgWarner announced it will expand its partnership with Great Wall Motor by launching two additional electrified propulsion projects utilizing advanced dual inverter technology, with mass production targeted for 2026. This collaboration provides Great Wall Motor with greater flexibility and efficiency in hybrid and plug-in hybrid development, supporting regulatory compliance and quicker product iterations for the competitive Chinese automotive market. We'll explore how...
SEHK:175
SEHK:175Auto

Is Geely a Bargain After 8% Pullback and Global EV Expansion Headlines?

Wondering if Geely Automobile Holdings is really a bargain or just looks like one? Let’s break down what’s driving its current price and see if there’s a hidden opportunity for investors like you. Geely’s shares have powered ahead with a 24.4% gain so far this year and are up 22.7% over the last 12 months, but have recently pulled back by around 8% in the past month. This might catch the attention of value hunters or raise questions about changing risks. This recent price drop comes on the...
SEHK:2162
SEHK:2162Biotechs

Why Is Keymed Biosciences (SEHK:2162) Drawing Big-Name Support After Stapokibart’s Approval in China?

Goldman Sachs recently initiated coverage on Keymed Biosciences, highlighting the approval of its first commercial product, stapokibart, in China for atopic dermatitis and chronic rhinosinusitis, while expressing confidence in the pipeline asset CM512 for asthma and COPD. This development underscores the growing recognition of Keymed's product pipeline and the confidence major institutions are placing in the company's future prospects. We'll explore how optimism for Keymed's pipeline,...